Observational studyESC heart failure2026
Demographics and clinical characteristics of Indian patients with heart failure visiting outpatient clinics: a cross-sectional observational study.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundData on heart failure (HF) phenotypes in India remain limited. We examined clinical characteristics and factors associated with HF phenotype defined according to ejection fraction (EF) in a large multicentre outpatient cohort.
methodsWe performed a retrospective cross-sectional analysis of adult HF outpatients with documented EF at centres across India (April 2021-March 2023). Patients were classified as HFrEF (EF ≤40%), HFmrEF (41%-49%), or HFpEF (≥50%); multivariable logistic regression identified factors associated with phenotype.
resultsAmong 1207 patients (62 ± 10 years; 73% male), HFrEF was present in 822 (68.1%), HFmrEF in 89 (7.4%), and HFpEF in 296 (24.5%). Patients with HFpEF had higher systolic blood pressure (153 ± 26 vs 122 ± 25 mmHg), higher body mass index (BMI; 27.5 ± 4.9 vs 26.4 ± 4.4 kg/m2), and more chronic kidney disease (45% vs 23%) and stroke (27% vs 6.2%) than those with HFrEF (all P ≤ .003). Ischaemic heart disease (66% vs 56%; P = .002) and higher NT-proBNP [median 3705 (481-6232) vs 140 (121-521) pg/ml; P < .001) were more common in HFrEF. In multivariable analysis, higher BMI [odds ratio (OR) 1.35 per 5 kg/m2, 95% confidence interval (CI) 1.10-1.65], higher systolic blood pressure (OR 1.48 per 10 mmHg, 95% CI 1.37-1.60), and stroke (OR 1.99, 95% CI 1.11-3.54) were associated with higher odds of HFpEF, whereas higher NT-proBNP (OR 0.46, 95% CI 0.40-0.53) and diabetes (OR 0.56, 95% CI 0.38-0.83) were associated with lower odds of HFpEF.
conclusionsHigher BMI and blood pressure were associated with HFpEF, whereas elevated NT-proBNP and diabetes were associated with HFrEF. These cross-sectional associations may support phenotype-specific management of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.